Ketamine for CRPS · St. Louis
Ketamine blocks the NMDA receptor that turns up RSD, CRPS and stubborn nerve pain. We use it by IV drip, under the tongue or as a cream once standard care has fallen short. Fill out the form and we will reach out for a private talk.
Prefer not to fill in a form?
Same-day and emergency appointments are available.
Ketamine is a non-competitive NMDA receptor antagonist. In plain terms, it blocks the NMDA receptor, a switch in the spinal cord that can turn pain up. Reflex sympathetic dystrophy (RSD) is also called complex regional pain syndrome (CRPS). In RSD and in other stubborn nerve pain, the pain signal fires over and over. That is thought to flood NMDA receptors in the spinal cord with glutamate, a nerve messenger. Over time, the volume keeps rising. That is the leading reason given for why a light touch can start to feel like an injury. It is worked out from the pattern of symptoms, not measured directly in patients. Blocking the NMDA receptor is why we consider ketamine after membrane-stabilizing medication (nerve-calming pills), sympathetic blocks and desensitization have not been enough.
At the Padda Institute Center for Interventional Pain Management we use ketamine three ways: intravenous infusion, sublingual forms that melt under the tongue, and topical cream rubbed on the painful area. For RSD and CRPS, we usually start with sublingual or topical.
The evidence does not transfer between these routes. A result from an IV study does not tell you what a cream will do. The reverse is just as true. If someone quotes an IV trial while handing you a jar of cream, those two things have little to do with each other. You should know that before you start.
The strongest data come from a randomized, double-blind trial of 60 patients with CRPS type 1 (Sigtermans and colleagues, Pain, 2009). A 100-hour continuous inpatient infusion of S(+)-ketamine lowered pain compared with placebo through about week 11. By week 12, the gap from placebo was gone. Two limits matter, and people rarely quote them. First, function did not improve. Only pain scores did. Second, 76 percent of patients had psychomimetic (mind-altering) side effects. That trial did not study short outpatient infusions, where you go home the same day.
The cream has its own body of research. One trial was double-blind, placebo-controlled and crossover, with 20 patients with CRPS (Finch and colleagues, Pain, 2009). In it, 10 percent ketamine cream cut brush allodynia (pain from a light brush) and punctate hyperalgesia (extra pain from a pinprick). No ketamine showed up in the blood — the effect stayed in the skin, not the whole body. Normal touch feeling did not change. No one measured how long the benefit lasts.
There is no controlled efficacy evidence for sublingual ketamine in these conditions. We will tell you so plainly. We use it because it is practical and easier to take than an IV drip — not because a trial has shown that it works.
For questions or concerns, fill out the form below.
Prefer not to fill in a form?
Same-day and emergency appointments are available.
Part of our complete guide to Interventional Pain Management in St. Louis.